Ardelyx to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022

To participate in the conference call, please dial (855) 296-9612 (domestic) or (920) 663-6277 (international) and refer to conference ID 2790368.

Metadata

Provider:

PR Newswire

Retrieved on:

Tuesday, February 22, 2022

Information

Tags:

Fosun Pharma, Knight Therapeutics, Investor, Webcast, Metabolic acidosis, CKD, ID, Therapy, Kidney, Adult, Multimedia, Hyperkalemia, View, Dialysis, Patient, Kyowa Hakko Kirin, Pharmaceutical industry

Geotags:

MASSACHUSETTS, CHINA, CANADA, JAPAN

Organisation:

ARDELYX

Stock Symbol:

NASDAQ-NMS:ARDX

Summary

Key Points:

To participate in the conference call, please dial (855) 296-9612 (domestic) or (920) 663-6277 (international) and refer to conference ID 2790368.
Ardelyx is focused on discovering, developing and commercializing innovative first-in-class medicines to meet significant unmet medical needs.
Ardelyx received approval for IBSRELA (tenapanor) with plans to launch in the second quarter of 2022.
Ardelyx is developing tenapanor, a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, which has completed three successful Phase 3 trials.

Ardelyx to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022

WALTHAM, Mass., Feb. 22, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that it will hold a conference call on Monday February 28, at 4:30 pm Eastern Time to discuss fourth quarter and year-end 2021 financial results and provide a corporate update.

To participate in the conference call, please dial (855) 296-9612 (domestic) or (920) 663-6277 (international) and refer to conference ID 2790368. Live audio of the conference call will be simultaneously webcast and will be available under the Investors section of the company's website at www.ardelyx.com. The webcast will be archived and available for replay for 30 days following the call.

About Ardelyx, Inc.

Ardelyx is focused on discovering, developing and commercializing innovative first-in-class medicines to meet significant unmet medical needs. Ardelyx received approval for IBSRELA (tenapanor) with plans to launch in the second quarter of 2022. Ardelyx is developing tenapanor, a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, which has completed three successful Phase 3 trials. Ardelyx is also advancing RDX013, a potassium secretagogue, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease and has an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in their respective territories.

View original content to download multimedia:https://www.prnewswire.com/news-releases/ardelyx-to-report-fourth-quarter-and-year-end-2021-financial-results-and-provide-corporate-update-on-february-28-2022-301487152.html

SOURCE Ardelyx